Efficacy, Safety and Dose Finding Trial of Topical Jaungo Application in Atopic Dermatitis Patients

Kyung Hee University

Status and phase: Completed; Phase 2

Conditions: Dermatitis, Atopic

Treatments: Drug: Placebo; Drug: Jaungo

Study type: Interventional

Funder types: Other

Identifiers

NCT02900131

ISEE_2015_JWG

Details and patient eligibility

About

Atopic Dermatitis is a chronic relapsing eczematous skin disease with increasing prevalence. Complementary and alternative medical approaches have been employed to relieve symptoms of Atopic Dermatitis. We aim to establish basic clinical efficacy and safety data for Jaungo in patients with Atopic Dermatitis.

Full description

This study is a randomised, double blind, placebo-controlled, single-centre trial with three parallel arms (trial group 1, trial group 2, and control group). The diagnosis of Atopic Dermatitis will be made according to the criteria of Hanifin and Rajka. Participants will receive Jaungo or a placebo-drug for three weeks. Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in trial group 2 will apply Jaungo to the lesion twice a day for three weeks. Participants in control group will apply placebo to the lesion twice a day for three weeks. Each participant will be examined for EASI (Eczema area and severity index), SCORAD (SCORing of Atopic Dermatitis), TEWL (Transepidermal water loss) and DLQI (Dermatology Life Quality Index) before and after applying medication. The outcomes to evaluate the maintenance of safety are Draize score, blood test and expert's opinion.

Enrollment: 34 patients

Sex: All

Ages: 5 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. The diagnosis of AD will be made according to the criteria of Hanifin and Rajka
2. Age: 5 years to 65 years
3. objective SCORAD ≦40, Diagnosis of Mild to Moderate Atopic Dermatitis (AD)
4. Exoriation≥1, Lichenification≥1, Dryness≥1 or Exoriation+Lichenification+Dryness≥3
5. Participants who able to express intention
6. Participants willing to provide written informed consent

Exclusion criteria

1. Participants have oozing in the lesion

2. Users of following medications prior to trial periods

   ① Oral steroids, immunosuppressants and antibiotics within 4 weeks prior to this trial

   ② Topical steroids, immunosuppressants and antibiotics within 2 weeks prior to this trial

   ③ Light therapy within 2 weeks prior to this trial

   ④ Other medications thought to be inappropriate by researchers

3. Participants have severe burn or wide wound

4. Participants have oozing or ulcer in the lesion

5. Allergic reactions to Angelica gigas, Siebold et Zuccarini, sesame oil and lard

6. Participants have skin disease except atopic dermatitis

7. Participants have severe renal function disease (sCr > 2.0 mg/dL)

8. Participants have severe liver function disease (ALT, AST, ALP ≥ 2.5 × normal limits)

9. Participants have uncontrolled chronic diseases

10. Pregnancy, lactation

11. Participation in another clinical trial within one month of enrolment

12. Underlying disease or history of severe disease, abnormal state (paralysis; mental retardation other emotional or mental problems; diseases that can affect the absorption of drugs; no enough time to participate in this trial; visual disturbance and hearing impairment; inability to understand written consent or engage in this study)

13. Judgment by experts that the potential subject's participation is inappropriate.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

34 participants in 3 patient groups, including a placebo group

trial group 1

Experimental group

Description:

Participants will receive Jaungo and placebo once a day for three weeks.

Treatment:

Drug: Jaungo

Drug: Placebo

trial group 2

Experimental group

Description:

Participants will receive Jaungo twice a day for three weeks.

Treatment:

Drug: Jaungo

control group

Placebo Comparator group

Description:

Participants will receive placebo twice a day for three weeks.

Treatment:

Drug: Placebo